Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Insulin 338 vs Insulin Glargine in Type 2 Diabetes
NCT02470039Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2015
- Primary completion
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Insulin 338 in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Jun 2015; status: completed.
02
Drugs
Insulin 338
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02470039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02470039.